deaths (OS)progression or deaths (PFS)RFS/DFS

Extensive stage SCLC (Es-SCLC) - maintenance (M) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - maintenance (M)

versus placebo
nivolumab alone vs. placebo 1 certainty unassessable-15% certainty unassessable-30%-

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus etoposide and platin vs. etoposide plus platin 1 certainty unassessablestatistically conclusive-25% certainty unassessable-20%-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-28% certainty unassessablestatistically conclusive-21%-
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessable-18% certainty unassessablestatistically conclusive-23%-